Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypertension as a predictive factor of Sunitinib activity.

× No keyword cloud information.

58 in total

Review 1. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors: Thomas Force; Kyle L Kolaja
Journal: Nat Rev Drug Discov Date: 2011-02 Impact factor: 84.694

2. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.

Authors: Franck Bürki; Kattalin Badie; Philippe Bartoli; Pascale Bernard; Jean Louis Montastruc; Haleh Bagheri
Journal: Br J Clin Pharmacol Date: 2008-02-15 Impact factor: 4.335

Review 3. Management of VEGF-Targeted Therapy-Induced Hypertension.

Authors: Stefano Caletti; Anna Paini; Maria Antonietta Coschignano; Carolina De Ciuceis; Matteo Nardin; Roberto Zulli; Maria Lorenza Muiesan; Massimo Salvetti; Damiano Rizzoni
Journal: Curr Hypertens Rep Date: 2018-06-29 Impact factor: 5.369

4. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.

Authors: Ying Chen; Brian I Rini; Angel H Bair; Ganesh M Mugundu; Yazdi K Pithavala
Journal: Clin Pharmacokinet Date: 2015-04 Impact factor: 6.447

Review 5. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

Authors: Alain Ravaud
Journal: Oncologist Date: 2011

6. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Authors: Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Journal: J Clin Oncol Date: 2010-01-19 Impact factor: 44.544

Review 7. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.

Authors: Wei-Xiang Qi; Ai-Na He; Zan Shen; Yang Yao
Journal: Br J Clin Pharmacol Date: 2013-09 Impact factor: 4.335

8. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

Authors: Bernard Paule; Laurence Bastien; Emmanuelle Deslandes; Olivier Cussenot; Marie-Pierre Podgorniak; Yves Allory; Benyoussef Naïmi; Raphael Porcher; Alexandre de La Taille; Suzanne Menashi; Fabien Calvo; Samia Mourah
Journal: PLoS One Date: 2010-05-19 Impact factor: 3.240

Review 9. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

Authors: S E Rosenbaum; S Wu; M A Newman; D P West; T Kuzel; M E Lacouture
Journal: Support Care Cancer Date: 2008-02-15 Impact factor: 3.603

10. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Authors: D A Reardon; A Desjardins; J J Vredenburgh; S Gururangan; J H Sampson; S Sathornsumetee; R E McLendon; J E Herndon; J E Marcello; J Norfleet; A H Friedman; D D Bigner; H S Friedman
Journal: Br J Cancer Date: 2009-11-17 Impact factor: 7.640